Inhibition of protein disulfide-isomerase A3
Provided are methods of treating a disease or condition associated with an increased level of expression of a protein disulfide-isomerase A3 (PDIA3) by administering to a subject with an increased level of expression of PDIA3 a PDIA3-inhibiting effective amount of a thiazolide compound, such as nitazoxanide or tizoxanide. Also provided are methods of screening for therapeutic agents based on PDIA3 inhibition.
1. A method of treating a disease or condition associated with an increased level of expression of protein disulfide-isomerase A3 comprising administering to a subject in need thereof a protein disulfide-isomerase A3-inhibiting effective amount of a pharmaceutical composition comprising at least one thiazolide compound, wherein the at least one thiazolide compound comprises (a) nitazoxanide or a pharmaceutically acceptable salt thereof, (b) tizoxanide or a pharmaceutically acceptable salt thereof or (c) a combination thereof, wherein the at least one thiazolide compound inhibits protein disulfide isomerase A3 more than it inhibits other protein disulfide isomerases, and wherein the disease or condition is a liver fibrosis or a renal fibrosis.
2. The method of claim 1 , wherein the thiazolide compound is nitazoxanide, tizoxanide, or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the pharmaceutical composition comprises nitazoxanide or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein the pharmaceutical composition comprises tizoxanide or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein the pharmaceutical composition comprises nitazoxanide and tizoxanide.
6. The method of claim 1 , wherein the disease or condition is a renal fibrosis.
7. The method of claim 1 , wherein the subject is a human being.
8. The method of claim 1 , wherein the disease or condition is a liver fibrosis.